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Introduction and objectives
Osteoarthritis is a disorder of movable joints,
characterized by degeneration and loss of articular
cartilage and the development of new bone on joint
surfaces. Repetitive mechanical forces cause damage to
healthy subchondral bone, cartilage and synovia leading
to the release of proteolytic enzymes that cause
cartilage fibrillation and breakdown of the proteoglycan
network.
Platelet-rich plasma (PRP)
Osteoarthritis 
Musculoskeletal injuries are the main cause of poor performance in horses and approximately 60% of lameness is related to osteoarthritis (OA).
PRP improves tissue regeneration and has been widely used in equine medicine, although few data are available regarding efficacy of this
treatment in horses with OA. The aim of this study is to review the most evidence based human and animal clinical trials and to compare the
effectiveness of PRP intra-articular injections with hyaluronic acid or placebo injections for the treatment of human and equine osteoarthritis.
References Species Duration
(months)
Treatment PRP injections 
/intervals(week)
Spinning approach PRP
activation
WBC Platelet 
concentration
Patel et al* 2013 Human 6 PRP vs saline 1-2/3 Single spinning + - <5xbaseline
Görmeli et al* 2015 Human 6 PRP vs HA 3/1 Double spinning + NA >5xbaseline
Kon et al 2011 Human 6 PRP vs HA 3/2 Double spinning + + >5xbaseline
Filardo et al* 2012a Human 12 PRP vs HA 3/1 Double spinning - + 5xbaseline
Cerza et al* 2012 Human 6 PRP vs HA 4/1 Single spinning - - >5xbaseline
Say et al 2013 Human 6 PRP vs HA 1 Single spinning + NA <5xbaseline
Filardo et al* 2011 Human 24 PRP 3/3 Double spinning + NA >5xbaseline
Filardo et al 2012b Human 12 PRGF vs PRP 3/3 Single vs double spinning + -/+ <5xbaseline
Sánchez et al* 2012 Human 6 PRGF vs HA 3/1 Single spinning + - <5xbaseline
Dallari et al* 2016 Human 12 PRP vs HA 3/1 Double spinning + NA NA
Cook et al* 2015 Canine 6 PRP vs saline 5/1-3 Single spinning + - <5xbaseline
Silva et al* 2013 Canine 3 PRP vs nutraceutical 3/2 Single spinning + - <5xbaseline
Abellanet 2007 Equine 36 PRP 1-3/1-2 Double spinning + + <5xbaseline
Conclusions
Platelet-rich plasma (PRP) is a blood-derived product
with platelet concentrations 2-8 times above baseline
levels. α-granules from activated platelets release a
large amount of growth factors (TGFβ, PDGF, HGF, VEGF,
IGF, FGF, CTGF) (Figure 1) which promote proliferation,
differentiation, chemotaxis and migration of various cell
types and stimulate extracellular matrix synthesis.
Some growth factors (VEGF, PDGF, TGFβ and FGF) also
stimulate and increase tissue angiogenesis. Growth
factors TGFβ and PDGF are the most measured.
PRP decreases nociception by inhibiting pro-
inflammatory cytokines and prostaglandins, stimulating
hyaluronic acid production and restoring homeostasis
balance.
Human, canine and equine clinical trials with an evidence degree level between 1 and 2 evaluating the use of intra-articular PRP for osteoarthritis
treatment show better clinical outcomes in those groups treated with PRP injections than those groups treated with hyaluronic acid or placebo.
PRP is more effective in joints with early osteoarthritis. The large variability in PRP composition between each clinical trial make it difficult to reach
any firm conclusions regarding efficacy of PRP. Multiple injections of PRP with low WBC concentration and 2-5 times over baseline platelet
concentration is recommended.
Larger, randomized clinical trials are needed to assess the effectiveness of PRP in treating osteoarthritis.
Table 2. Clinical studies using PRP injections to treat osteoarthritis
*Randomised controlled trial
NA: not applicable; PRP: platelet-rich plasma; WBC: white blood cells
Osteoarthritis PRP action mechanisms
Synovium Synovyocites are a rich source of
prostaglandins, cytokines and
matrix metalloproteinases that
contribute to the cartilage
matrix depletion.
FGF increases hyaluronic acid
production and secretion in
synovyocites.
Cartilage Metalloproteinases, catabolic
cytokines (IL-1 and TNFα), nitric
oxide and prostaglandin E2
degradate cartilage extracellular
matrix and inhibit the synthesis
of proteoglycans and type II
collagen.
Growth factors promote chondrocyte
proliferation and differentiation and
the synthesis of type II collagen and
proteoglycans.
TGFβ has antiinflamatory properties as
it inhibits catabolic cytokines (IL-1,
TNFα) and stimulates IL-1 receptor
antagonist.
Bone There is loss of balance between
resorption and remodeling functions
of osteoclasts and osteoblasts. IL-1
stimulates osteoblast-like cells
causing osteophytosis.
PDGF, VEGF and IGF stimulate osteoblast
proliferation and differentiation in
subchondral bone.
Figure 1
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